Regulatory Beat: Changes and Challenges at FDA - Manufacturers will find some controversial initiatives delayed, while efforts continue to address product safety concerns - BioPharm International

ADVERTISEMENT

Regulatory Beat: Changes and Challenges at FDA
Manufacturers will find some controversial initiatives delayed, while efforts continue to address product safety concerns


BioPharm International



Jill Wechsler
After months of turmoil over drug safety, vaccine shortages, and pressure to import low-cost drugs from abroad, FDA faces further upheaval from within. Commissioner Lester Crawford resigned abruptly in September after only two months in the top spot. The White House named Andrew von Eschenbach, director of the National Cancer Institute (NCI) at the National Institutes of Health (NIH), as acting FDA commissioner. But his initial decision to remain NCI director while taking the helm of FDA raised an outcry. Von Eschenbach agreed to drop day-to-day management of NCI in the face of clear conflicts of interest between advocating for speedy access to new cancer treatments while overseeing the assessment of the safety and effectiveness of those therapies.

Von Eschenbach reassured FDA staffers that he would work hard to ensure a "smooth transition" and to keep agency efforts "on track." FDA leaders insist they will carry on as usual during the transition to new leadership. Following Crawford's terse resignation announcement, Deputy Commissioners Scott Gottlieb, Janet Woodcock, Murray Lumpkin, and Patrick Ronan sent a message to all FDA employees emphasizing their commitment to the agency and intention of continuing its important work. Von Eschenbach is familiar with the FDA drug testing and review process from collaborative NCI-FDA efforts. He has been enthusiastic about joint initiatives to validate biomarkers and advance personalized medicine.

Von Eschenbach also is highly regarded in the cancer research field, knows his way around Capitol Hill, and has personal connections to the Bush family from his leadership position at Houston's M.D. Anderson Cancer Center. Cancer patient groups have praised his support for accelerating access to new treatments, and biotech companies publicly applauded the choice. James Greenwood, president of the Biotechnology Industry Organization, described the acting commissioner as someone with "unique insights into the critical need to advance new treatments for patients with life-threatening illnesses."

NOTHING PERMANENT

However, von Eschenbach officially remains director of NCI, a position he wants to retain because HHS secretary Mike Leavitt has indicated that the acting commissioner will not be named to take the reins at FDA permanently. Von Eschenbach's enthusiasm for approving new drugs quickly has drawn fire from parties that are equally concerned about protecting relatively healthy patients from high-risk medicines. In addition, the acting commissioner knows little about the many complex and critical regulatory programs that FDA oversees, such as concerns about the safety and testing of implantable medical devices. FDA staffers already are finding it difficult to move forward with controversial initiatives. A much-anticipated white paper on follow-on biologics, for example, won't be released any time soon, apparently to give the lawyers time to further examine policy and legal issues.

At FDA, von Eschenbach has to deal with many of the issues that plagued Crawford and delayed his confirmation by the Senate last spring. FDA still faces proposals from Congress to overhaul its oversight of drug safety arising from the Vioxx debacle, to ensure adequate supplies of vaccines for influenza and childhood diseases, and to permit broader access to the morning-after pill, Plan B. Although Congressional leaders, manufacturers, and the bioresearch community have urged the White House to name a qualified individual for that spot as soon as possible to head FDA permanently, the cloud hanging over Crawford's departure won't make it easy to attract a talented scientist and administrator to the job. Senate Democrats refuse to consider candidates with ties to the pharmaceutical industry, and conservative Republicans want someone who shares their political views. Current FDA officials face difficulties because of close ties to recent agency missteps. Further complicating the picture is an investigation into the reasons for Crawford's surprise resignation; Senate leaders who backed Crawford's appointment want to know whether they were denied access to important information during the confirmation process. FDA desperately needs a strong leader who can restore public trust in the troubled agency – but this may be hard to find.

ASSESSING SAFETY

An immediate challenge for FDA's leadership is to reassure its constituents that drug safety problems are not creating a go-slow approach in FDA review offices. Some observers believe that safety concerns are delaying the approval of important new therapies, and that advisory committee meetings spend more time than is warranted discussing minor adverse events. FDA recently postponed approval of Celgene's blood disorder treatment, Revlimid (lenalidomide), pending further review of the company's risk-management plan for preventing pregnant women from using this newer version of thalidomide.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here